Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11117017 | 0.86 | NOTUM (0.56) | NOTUMF2USP2ALDH1A1KMT2A | |
| SCHEMBL30136136 | 0.79 | NOTUM (0.53) | NOTUMF2USP2ALDH1A1KMT2A | |
| SCHEMBL29958128 | 0.79 | NOTUM (0.53) | NOTUMF2USP2ALDH1A1KMT2A | |
| SCHEMBL29757989 | 0.79 | NOTUM (0.53) | NOTUMF2ALDH1A1KMT2AKDM4E | |
| SCHEMBL16615357 | 0.79 | NOTUM (0.53) | NOTUMF2USP2ALDH1A1KMT2A | |
| SCHEMBL23466554 | 0.79 | NOTUM (0.53) | NOTUMF2ALDH1A1KMT2AKDM4E | |
| SCHEMBL3009848 | 0.79 | NOTUM (0.53) | NOTUMF2USP2ALDH1A1KMT2A | |
| SCHEMBL8177591 | 0.79 | NOTUM (0.53) | NOTUMF2USP2ALDH1A1KMT2A | |
| SCHEMBL29141786 | 0.79 | NOTUM (0.49) | NOTUMF2USP2ALDH1A1KMT2A | |
| SCHEMBL10290211 | 0.76 | NOTUM (0.46) | NOTUMF2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3247354-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10123995-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180265494-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-20 | — | — | US | disclosed |
| EP-2899183-B1 | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180000795-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3247354-A1 | FACTOR XIA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170305880-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| US-9783530-B2 | Factor Xla inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20100016316-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-21 | — | — | US | disclosed |
| CN-101605779-A | Arylprop acid amides, aryl acrylamide, arylprop alkynyl amide or arylmethyl urea analogue as plasma thromboplastin antecedent A inhibitor | BRISTOL MYERS SQUIBB CO (US) | 2009-12-16 | — | — | CN | disclosed |
| US-7626039-B2 | Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-2102189-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | disclosed |
| CN-101341129-A | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | CN | disclosed |
| EP-1981854-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | disclosed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | NOTUM 2445/4885F2 8/4885USP2 1152/4885 |
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | F12, TFPI, F11 | NOTUM 1548/4885F2 6/4885USP2 4242/4885 |
| US-20100016316-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | F12, TFPI, F11 | NOTUM 2886/4885F2 9/4885USP2 1352/4885 |
| US-20170305880-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | NOTUM 781/4885F2 11/4885USP2 4131/4885 |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | TFPI, F12, F11 | NOTUM 559/4885F2 7/4885USP2 3979/4885 |
| US-20180265494-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | NOTUM 781/4885F2 11/4885USP2 4131/4885 |
| US-10123995-B2 | Factor XIa inhibitors | F11, SERPINC1, TFPI | NOTUM 757/4885F2 4/4885USP2 2818/4885 |
| US-20180000795-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | NOTUM 757/4885F2 4/4885USP2 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.